The U.S. Pharmacopeial Convention, biosimilar makers, payers and pharmacists are concerned the Senate health committee's plan to exempt biologics from compendial standards would clear the way for FDA to take sole responsibility for establishing nonproprietary names for these products and avoid a public process. A USP spokesperson told Inside Health Policy that the measure, tucked into the committee's health innovation package, would preempt stakeholder dialogue on nonproprietary naming solutions for biologics. USP, along with several groups such as The...